Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
INGN 201
GENETIC
4 trials
Sponsors
Introgen Therapeutics
, M.D. Anderson Cancer Center
Conditions
Carcinoma, Squamous Cell
Locally Advanced Breast Cancer (LABC)
Mouth Cancer
Phase 1
Wild Type p53 Adenovirus for Oral Premalignancies
Terminated
NCT00410865
M.D. Anderson Cancer Center
Mouth Cancer
Start: 2003-06-30
End: 2010-11-30
Updated: 2011-12-07
Phase 2
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer
Completed
NCT00286247
Introgen Therapeutics
Locally Advanced Breast Cancer (LABC)
Target: 60
Updated: 2008-04-01
Phase 3
Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
NCT00041613
Introgen Therapeutics
Carcinoma, Squamous Cell
Updated: 2008-04-01
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
NCT00041626
Introgen Therapeutics
Carcinoma, Squamous Cell
Updated: 2007-09-11